Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Kunming Qingcheng Healthcare Tech Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This case is assigned to 1 distinct examiner and 1 distinct art unit, which simplifies the current prosecution landscape for the company. This concentration means that all active patent office interactions are funneled through a single point of contact.
OLSON, ANDREA STEFFEL is the busiest examiner, managing the 1 pending office action. As there is only 1 distinct examiner for the entire pending portfolio, the company's immediate results are tied to this single official's assessment. There are no other pending actions to provide a baseline for how different examiners might view the company's biotechnology technology.
For practitioners, the presence of 1 pending office action in 1 distinct art unit suggests a highly focused prosecution strategy. Every effort must be made to address the specific concerns of OLSON, ANDREA STEFFEL, as this examiner holds the key to the company's current patenting success. The lack of a broader pending portfolio means that this single action carries significant weight for the company's intellectual property position.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OLSON, ANDREA STEFFEL | 1 | 62.4% | -11.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18420246 | DISINFECTANT AND DISINFECTION METHOD FOR EFFECTIVELY KILLING ENDOSPORES | OLSON, ANDREA STEFFEL | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18420246 | DISINFECTANT AND DISINFECTION METHOD FOR EFFECTIVELY KILLING ENDOSPORES | OLSON, ANDREA STEFFEL | 1693 | §102§103 | Final Rejection | — | Pending | Jan 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKunming Qingcheng Healthcare Tech Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Andrea Steffel Olson has the most, with 1 of Kunming Qingcheng Healthcare Tech Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
